CCM3/SERPINI1 bidirectional promoter variants in patients with cerebral cavernous malformations: a molecular and functional study
- PMID: 27737651
- PMCID: PMC5064884
- DOI: 10.1186/s12881-016-0332-0
CCM3/SERPINI1 bidirectional promoter variants in patients with cerebral cavernous malformations: a molecular and functional study
Abstract
Background: Cerebral cavernous malformations (CCMs) are vascular anomalies of the nervous system mostly located in the brain presenting sporadically or familial. Causes of familial forms are mutations in CCM1 (Krit1), CCM2 (MGC4607) and CCM3 (PDCD10) genes. Sporadic forms with no affected relative most often have only one lesion and no germ line mutations. However, a number of sporadic cases with multiple lesions have been reported and are indeed genetic cases with a de novo mutation or a mutation inherited from an asymptomatic parent.
Methods: Here, we performed an analysis of regulatory region of CCM genes in 60 sporadic patients, negative for mutations in coding region and intron-exon boundaries and large deletion/duplications in CCM genes by direct sequencing and MLPA. Among 5 variants identified in 851-bp region shared by CCM3 and SERPINI1 genes and acting as asymmetric bidirectional promoter, two polymorphisms c.-639 T > C/rs9853967 and c.-591 T > C/rs11714980 were selected. A case-control study was performed to analyze their possible relationships with sporadic CCMs. Promoter haplotypes activities on CCM3/SERPINI1 genes expression were tested by dual-luciferase assay.
Results: No variants were identified in CCM1 and CCM2 regulatory regions. In CCM3/SERPINI1 asymmetric bidirectional promoter 5 variants, 2 of them unknown and 3 corresponding to polymorphisms c.-639 T > C/rs9853967, c.-591 T > C/rs11714980 and c.-359G > A/rs9834676 were detected. While rs9853967 and rs11714980 polymorphisms fall in a critical regulatory fragment outside the minimal promoter in intergenic region, other variants had no effects on transcription factor binding according to RegRNA tool. Case-control study performed on 60 patients and 350 healthy controls showed frequencies of the mutated alleles significantly higher in the control group than in patients. Furthermore, the functional assay showed a significant reduction of CCM3 expression for C-C haplotype even more than for T-C and C-T haplotypes. In SERPINI1 direction, the reduction was not statistically significant.
Conclusions: Our data indicated that rs9853967 and rs11714980 polymorphisms could be associated with a protective role in CCM disease.
Keywords: Association study; Bidirectional promoter; CCM genes; CCM3/SERPINI1; Dual luciferase-assay; Polymorphism.
Figures
Similar articles
-
Relevance of CCM gene polymorphisms for clinical management of sporadic cerebral cavernous malformations.J Neurol Sci. 2017 Sep 15;380:31-37. doi: 10.1016/j.jns.2017.06.043. Epub 2017 Jun 29. J Neurol Sci. 2017. PMID: 28870584
-
CCM2 gene polymorphisms in Italian sporadic patients with cerebral cavernous malformation: a case-control study.Int J Mol Med. 2012 Jun;29(6):1113-20. doi: 10.3892/ijmm.2012.927. Epub 2012 Feb 28. Int J Mol Med. 2012. PMID: 22378217
-
High-throughput sequencing of the entire genomic regions of CCM1/KRIT1, CCM2 and CCM3/PDCD10 to search for pathogenic deep-intronic splice mutations in cerebral cavernous malformations.Eur J Med Genet. 2017 Sep;60(9):479-484. doi: 10.1016/j.ejmg.2017.06.007. Epub 2017 Jun 20. Eur J Med Genet. 2017. PMID: 28645800
-
Molecular diagnosis in cerebral cavernous malformations.Neurologia. 2017 Oct;32(8):540-545. doi: 10.1016/j.nrl.2015.07.001. Epub 2015 Aug 21. Neurologia. 2017. PMID: 26304651 Review. English, Spanish.
-
Cerebral cavernous malformations: from CCM genes to endothelial cell homeostasis.Trends Mol Med. 2013 May;19(5):302-8. doi: 10.1016/j.molmed.2013.02.004. Epub 2013 Mar 15. Trends Mol Med. 2013. PMID: 23506982 Review.
Cited by
-
Genetic Polymorphisms in VEGFR Coding Genes (FLT1/KDR) on Ranibizumab Response in High Myopia and Choroidal Neovascularization Patients.Pharmaceutics. 2022 Jul 26;14(8):1555. doi: 10.3390/pharmaceutics14081555. Pharmaceutics. 2022. PMID: 35893809 Free PMC article.
-
GLO1 gene polymorphisms and their association with retinitis pigmentosa: a case-control study in a Sicilian population.Mol Biol Rep. 2018 Oct;45(5):1349-1355. doi: 10.1007/s11033-018-4295-4. Epub 2018 Aug 11. Mol Biol Rep. 2018. PMID: 30099685
-
Recent advances in cerebral cavernous malformation research.Vessel Plus. 2018;2:21. doi: 10.20517/2574-1209.2018.34. Epub 2018 Aug 28. Vessel Plus. 2018. PMID: 31360916 Free PMC article.
-
Rosiglitasone and ROCK Inhibitors Modulate Fibrogenetic Changes in TGF-β2 Treated Human Conjunctival Fibroblasts (HconF) in Different Manners.Int J Mol Sci. 2021 Jul 8;22(14):7335. doi: 10.3390/ijms22147335. Int J Mol Sci. 2021. PMID: 34298955 Free PMC article.
-
Investigating Müller glia reprogramming in mice: a retrospective of the last decade, and a look to the future.Neural Regen Res. 2025 Apr 1;20(4):946-959. doi: 10.4103/NRR.NRR-D-23-01612. Epub 2024 Apr 16. Neural Regen Res. 2025. PMID: 38989930 Free PMC article.
References
-
- Zabramski JM, Henn JS, Coons S. Pathology of cerebral vascular malformations. Neurosurg Clin N Am. 1999;10(3):395–410. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources